Equibles does not estimate personal net worth.
J. Joseph Kim was last confirmed as Board Member and CEO at Inovio Pharmaceuticals, Inc. (INO) in a filing dated March 28, 2023. Earlier roles on record: CEO and Board Member at Inovio Pharmaceuticals, Inc. (INO) until May 10, 2022. The proxy statement of Inovio Pharmaceuticals, Inc. reports total compensation of $10,472,297 for J. Joseph Kim in fiscal 2022, including a base salary of $523,714. Disclosed compensation is on record for 6 fiscal years. J. Joseph Kim has spoken on 8 earnings calls across 1 company, most recently for Inovio Pharmaceuticals, Inc. on December 31, 2021. The companies whose calls J. Joseph Kim spoke on are classified in the Healthcare sector.
“I appreciate everyone taking the time to join us today. The impact of the highly transmissible Omicron variant of SARS-CoV-2 over the past few months highlights the enduring threat of COVID-19, particularly the unpredictability of current and future variants of concern.”
“I appreciate you taking the time to join us this afternoon. Let me begin by stating how pleased I am with the progress that we've made over the last few months.”
“With COVID-19 rates surging again globally and the increasing number of breakthrough infections, Inovio recognizes the need for additional safe and effective first-line vaccines, particularly those which could offer potential boosting capabilities to combat the spread of the virus and emerging variants, including the…”
“Thank you, Ben, and thank you to everyone for taking the time to join us for today's call. When we last connected, we were in a very different place, awaiting the impact of holiday travel and gatherings on community viral spread, particularly given the emergence of variant strains around the world.”
“We have a lot to discuss following this afternoon’s Phase 3 VGX-3100 announcement. And I want to ensure we cover our other key programs and allow time for endless questions.”
Start not stated–2023-03-28
Last confirmed by a filing; no departure on record
Start not stated–2023-03-28
Last confirmed by a filing; no departure on record
Start not stated–2022-05-10
Start not stated–2022-05-10
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Inovio Pharmaceuticals, Inc. (INO) | Former President and Chief Executive Officer | $523,714 | $10,472,297 |
| 2021 | Inovio Pharmaceuticals, Inc. (INO) | Former President and Chief Executive Officer | $844,056 | $6,223,600 |
| 2020 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $694,645 | $4,707,676 |
| 2019 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $837,735 | $2,588,534 |
| 2018 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $726,798 | $3,081,043 |
| 2017 | Inovio Pharmaceuticals, Inc. (INO) | President, Chief Executive Officer and Director | $780,007 | $4,389,268 |
